19. Anti-inflammatory effects of intravenous immunoglobulin: Fcgamma receptor inhibition/blockade and non-Fcgamma receptor-mediated mechanisms (English)
- New search for: Semple, J. W.
- New search for: Lazarus, A. H.
- New search for: Semple, J. W.
- New search for: Lazarus, A. H.
- New search for: Dalakas, M. C.
- New search for: Spath, P. J.
In:
International symposium on the use of intravenous immunoglobulin (IVIG)
;
127-132
;
2004
-
ISBN:
- Conference paper / Print
-
Title:19. Anti-inflammatory effects of intravenous immunoglobulin: Fcgamma receptor inhibition/blockade and non-Fcgamma receptor-mediated mechanisms
-
Contributors:
-
Conference:5th, International symposium on the use of intravenous immunoglobulin (IVIG) ; 2003 ; Interlaken, Switzerland
-
Published in:
-
Publisher:
- New search for: Parthenon,
-
Place of publication:Boca Raton , London:
-
Publication date:2004-01-01
-
Size:6 pages
-
Remarks:Includes bibliographical references and index
-
ISBN:
-
Type of media:Conference paper
-
Type of material:Print
-
Language:English
-
Keywords:
-
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents conference proceedings
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 3
-
1. Manufacturing of intravenous immunoglobulin: challenges, achievements and opportunitiesMorell, A. et al. | 2004
- 9
-
2. Challenges and achievements in pathogen safety of intravenous immunoglobulinSpath, P. J. / Kempf, C. et al. | 2004
- 21
-
3. Treatment modalities and clinical efficacy of immunoglobulin G replacement therapies in primary immunodeficiencyWebster, A. D. B. et al. | 2004
- 29
-
4. Immunomodulation by intravenous immunoglobulin: idiopathic thrombocytopenic purpura as a modelImbach, P. et al. | 2004
- 37
-
5. Witnessing the introduction and use of intravenous immunoglobulin in neurologyDalakas, M. C. et al. | 2004
- 41
-
6. Pharmacoeconomics of intravenous immunoglobulin administration in neurological disorders: the US experienceDonofrio, P. D. et al. | 2004
- 47
-
7. Pharmacoeconomics of intravenous immunoglobulin for polyneuropathiesMcCrone, P. et al. | 2004
- 53
-
8. B-cell maturation to produce high-affinity antibodies of different isotypes and its abnormalitiesDurandy, A. et al. | 2004
- 57
-
9. The molecular basis of primary immune deficiency diseasesOchs, H. D. / Torgerson, T. R. / Lee, W.-I. / Jin, Y. Z. / Gambineri, E. / Zhu, Q. et al. | 2004
- 71
-
10. Safety in intravenous immunoglobulin therapyGelfand, E. W. et al. | 2004
- 77
-
11. Immunoglobulin replacement by the subcutaneous route using preparations licensed in the USA for administration by other routesBerger, M. / Duff, K. / Poll, J. / Roy, S. et al. | 2004
- 81
-
12. The use of intravenous immunoglobulin for allogeneic stem cell transplantation: the US experienceBuckley, R. H. et al. | 2004
- 85
-
13. Intravenous immunoglobulin for bone marrow/stem cell transplantation: the European experienceTheunissen, K. / Maertens, J. A. / Boogaerts, M. A. et al. | 2004
- 91
-
14. Secondary antibody deficiency following treatment of vasculitis: the use of intravenous immunoglobulinTormey, V. J. / Burns, A. et al. | 2004
- 95
-
15. Intravenous immunoglobulin in the prevention and treatment of severe infectionsWerdan, K. et al. | 2004
- 105
-
16. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseasesKazatchkine, M. D. / Bayry, J. / Lacroix-Desmazes, S. / Kaveri, S. V. et al. | 2004
- 113
-
17. Role of intravenous immunoglobulin in reversing glucocorticoid insensitivity or resistanceGelfand, E. W. et al. | 2004
- 121
-
18. Modulating the balance of activating and inhibiting Fcgamma receptors: mechanism of intravenous immunoglobulin actionPricop, L. et al. | 2004
- 127
-
19. Anti-inflammatory effects of intravenous immunoglobulin: Fcgamma receptor inhibition/blockade and non-Fcgamma receptor-mediated mechanismsSemple, J. W. / Lazarus, A. H. et al. | 2004
- 133
-
20. Immune modulation by intravenous immunoglobulin: some remarks on the role of Fc receptorsvan Mirre, E. / Hack, C. E. et al. | 2004
- 137
-
21. Intravenous immunoglobulin in reactive hemophagocytic syndrome: a paradigm of Fcgamma receptor and cytokine modulationMouthon, L. et al. | 2004
- 143
-
22. Anti-inflammatory effects of intravenous immunoglobulin through modulation of complement activitiesLutz, H. U. / Spath, P. J. et al. | 2004
- 149
-
23. Changes in gene expression profile in the muscles of patients with dermatomyositis and inclusion body myositis after therapy with intravenous immunoglobulin: a microarray analysis correlating gene expression with clinical outcomeRaju, R. / Dalakas, M. C. et al. | 2004
- 153
-
24. In vitro studies of mechanisms of action of intravenous immunoglobulin in Guillain-Barre syndrome and Miller-Fisher syndrome: a reviewGold, R. / Weishaupt, A. / Stangel, M. / Chan, A. / Toyka, K. V. et al. | 2004
- 161
-
25. The immunological rationale for intravenous immunoglobulin in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathyPollard, J. D. et al. | 2004
- 171
-
26. Intravenous immunoglobulin for Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy in adult patientsvan Doorn, P. A. et al. | 2004
- 181
-
27. Clinical experience with intravenous immunoglobulin for treatment of pediatric Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathyKornberg, A. J. et al. | 2004
- 187
-
28. Intravenous immunoglobulin for multifocal motor neuropathyvan den Berg, L. H. et al. | 2004
- 191
-
29. Intravenous immunoglobulins in paraproteinemic demyelinating neuropathiesLeger, J.-M. et al. | 2004
- 197
-
30. Immunoglobulins in IgM antimyelin-associated glycoprotein and other paraproteinemic neuropathiesComi, G. et al. | 2004
- 203
-
31. Intravenous immunoglobulin for myasthenia gravisGajdos, P. et al. | 2004
- 207
-
32. Intravenous immunoglobulin in polymyositis and dermatomyositisCherin, P. et al. | 2004
- 213
-
33. Controlled studies with high-dose intravenous immunoglobulin in the treatment of inclusion body myositisDalakas, M. C. et al. | 2004
- 221
-
34. Immune mechanisms and treatment perspectives in multiple sclerosisHohlfeld, R. et al. | 2004
- 229
-
35. A review of controlled clinical trials of intravenous immunoglobulin in multiple sclerosisSorensen, P. S. et al. | 2004
- 235
-
36. Intravenous immunoglobulin treatment for patients with primary or secondary progressive multiple sclerosisPohlau, D. / Kallweit, U. et al. | 2004
- 243
-
37. What is the effective dose of intravenous immunoglobulin for treatment of relapsing-remitting multiple sclerosis?Lewanska, M. / Siger-Zajdel, M. / Selmaj, K. et al. | 2004
- 257
-
38. High-dose intravenous immunoglobulin in the treatment of patients with stiff person syndrome: a controlled studyDalakas, M. C. et al. | 2004
- 267
-
39. Intravenous immunoglobulin in acute disseminated encephalomyelitisMarchioni, E. / Ravaglia, S. / Todeschini, A. / Pichiecchio, A. / Uggetti, C. / Piccolo, G. / Ceroni, M. et al. | 2004
- 279
-
40. Intravenous immunoglobulin in dermatologyJolles, S. et al. | 2004
- 283
-
41. The use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseasesAhmed, A. R. et al. | 2004
- 291
-
42. Treatment of atopic dermatitis, urticaria and psoriasis with intravenous immunoglobulinRustin, M. et al. | 2004
- 297
-
43. Intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndromeFrench, L. E. et al. | 2004
- 301
-
44. Intravenous immunoglobulin in the treatment of vasculitisJayne, D. et al. | 2004
- 313
-
45. Immunomodulation by intravenous immunoglobulin of alloantibodies to human leukocyte antigen: clinical aspects in solid organ transplantationGlotz, D. / Antoine, C. / Julia, P. / Pegaz-Fiornet, B. / Duboust, A. / Boudjeltia, S. / Fraoui, R. / Combes, M. / Bariety, J. et al. | 2004
- 321
-
46. Role of intravenous immunoglobulin in the management of heart failureKrum, H. et al. | 2004
- 331
-
47. Intravenous immunoglobulin: potential role in the management of severe acute respiratory syndromeChng, H. H. / Leong, K. P. / Leung, B. / Ang, B. / Leo, Y. S. / Loo, S. / Goh, S. K. / Lew, T. W. K. / Hsu, L. Y. / Arul, E. et al. | 2004
- 337
-
48. Enhancement of the immune response to Mycobacterium tuberculosis by high-dose intravenous immunoglobulin in miceJolles, S. / Roy, E. / Stavropoulos, V. / Coade, S. / Grigorieva, E. / Tascon, R. / Lowrie, D. et al. | 2004
- 343
-
49. Intravenous immunoglobulin for treatment of recurrent miscarriageNoens, L. A. E. et al. | 2004
- 349
-
50. Epilepsy and the immune system: is there a link?Lagae, L. G. et al. | 2004
- 357
-
51. Intravenous immunoglobulin as an immunomodulatory agent in systemic lupus erythematosus and lupus nephritisSherer, Y. / Shoenfeld, Y. et al. | 2004
- 361
-
52. Intravenous immunoglobulin for fibrosis, atherosclerosis and malignant conditionsKrause, I. / Shoenfeld, Y. et al. | 2004
- 369
-
53. Intravenous immunoglobulin for immune deficiencies and passive immunizationQuinti, I. / Cagliuso, M. / Aiuti, F. et al. | 2004
- 373
-
54. The use of intravenous immunoglobulin in hematology and transplantationProvan, D. et al. | 2004
- 377
-
55. The use of intravenous immunoglobulin in neurologyEngel, W. K. et al. | 2004
- 383
-
56. The use of intravenous immunoglobulin for dermatological disordersSticherling, M. et al. | 2004
- 389
-
57. The use of intravenous immunoglobulin in collagen vascular and heart diseasesLazarus, A. H. et al. | 2004
- 393
-
58. Intravenous immunoglobulin: mechanisms of actionWilliams, P. E. et al. | 2004
- 399
-
59. Pathogen safety and tolerability of intravenous immunoglobulinRossi, F. et al. | 2004
- 405
-
60. Pharmacoeconomics and evidence-based medicineAntonini, G. / Di Pasquale, A. et al. | 2004